VacciMonitor (Dec 2014)

Establishment of an in vivo potency assay for the recombinant hepatit is B surface antigen in monovalent and combined vaccines

  • Mabel Izquierdo-López,
  • Karelia Cosme-Diaz,
  • Gerardo García-Illera,
  • Zoe Núñez-Lamotte,
  • Yamila Martínez- Cuéllar,
  • Maribel Vega-Simón,
  • Lourdes Costa-Anguiano,
  • Marisel Quintana-Esquivel,
  • Ileana Rosales-Torres,
  • Omar Mosqueda-Lobaina

Journal volume & issue
Vol. 23, no. 3
pp. 83 – 90

Abstract

Read online

In this paper the development of potency assay in animals (mice) was made, with the objective of demonstrating the immunogenic power of the recombinant Hepatitis B surface antigen in monovalent and combined vaccines, produced at the Center of Genetic Engineering and Biotechnology. The potency test is a parameter in quality control and it is also a tool to demonstrate the consistency of the production process. Parameters such as duration of the test, number of animals in the test, as well as different areas for the maintenance of the animals were evaluated. The results on the applicability of the potency test, to two presentations of the vaccines; monovalent Heberbiovac HB and pentavalent liquid in one vial Heberpenta-L are shown, for which specificity studies, evaluating different vaccine lots, the behavior of linearity, and parallelism, as well as establishing quality specification of the test were performed. This assay led to the obtainment of reliable results for the vaccines evaluated, the consistent evaluation of the immunogenic power and the monitoring of different production processes.

Keywords